Truist Maintains Biogen Buy Rating, Raises Target to $260
Truist Securities raised its Biogen price target to $260 from $235 while maintaining its Buy rating.
Story updates
02:48:25 PM UTC
SquawkNews
Biogen Price Target Raised to $260.00/Share From $235.00 by Truist Securities